US5194569A
(en)
*
|
1991-10-18 |
1993-03-16 |
Akzo Nv |
Synthesis of block liquid crystal copolymer
|
US5258486A
(en)
*
|
1992-07-31 |
1993-11-02 |
Akzo Nv |
Synthesis of block liquid crystal copolymer
|
DE19704506A1
(de)
*
|
1997-02-06 |
1998-08-13 |
Basf Ag |
Chiral nematische Polyester
|
CN1371416B
(zh)
|
1999-08-24 |
2012-10-10 |
梅达里克斯公司 |
人ctla-4抗体及其应用
|
US7560534B2
(en)
|
2000-05-08 |
2009-07-14 |
Celldex Research Corporation |
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
|
EP1494714A4
(de)
|
2002-04-05 |
2008-03-05 |
Amgen Inc |
Humane anti-opgl-neutralisierende antikörper als selektive opgl-pfad-hemmer
|
EA018072B1
(ru)
|
2002-09-06 |
2013-05-30 |
Амджен Инк. |
Антитело к рецептору интерлейкина-1 типа 1 (il-1r1) и его применение
|
KR20090088973A
(ko)
|
2002-10-17 |
2009-08-20 |
젠맵 에이/에스 |
Cd20에 대한 인간 모노클로날 항체
|
EP1533617A1
(de)
|
2003-11-19 |
2005-05-25 |
RMF Dictagene S.A. |
Angiogenese inhibierende Moleküle, deren Auswahl, Herstellung und Benutzung zur Behandlung und Diagnose von Krebs
|
US7642341B2
(en)
|
2003-12-18 |
2010-01-05 |
Merck Serono S.A. |
Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
|
AU2005320349C1
(en)
|
2004-02-06 |
2019-06-13 |
E. R. Squibb & Sons, L.L.C. |
Antibodies against clostridium difficile toxins and uses thereof
|
EP2360186B1
(de)
|
2004-04-13 |
2017-08-30 |
F. Hoffmann-La Roche AG |
Antikörper gegen P-Selectin
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
ES2414460T3
(es)
|
2004-08-04 |
2013-07-19 |
Amgen Inc. |
Anticuerpos para Dkk-1
|
EP2535355B1
(de)
|
2005-03-23 |
2019-01-02 |
Genmab A/S |
Antikörper gegen CD38 zur Behandlung von multiplem Myelom
|
NO345593B1
(no)
|
2005-07-18 |
2021-05-03 |
Amgen Inc |
Humane anti-B7RP1 nøytraliserende antistoffer
|
NZ576122A
(en)
|
2006-09-26 |
2012-09-28 |
Genmab As |
Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
|
EP2068928A2
(de)
|
2006-09-28 |
2009-06-17 |
Merck Serono SA |
Junctional adhesion molecule-c (jam-c) bindende verbindungen und anwendungsverfahren davon
|
KR101518081B1
(ko)
|
2007-02-21 |
2015-05-06 |
유니버시티 오브 매사추세츠 |
C형 간염 바이러스(hcv)에 대한 인간 항체 및 이것의 용도
|
WO2008119353A1
(en)
|
2007-03-29 |
2008-10-09 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
EP4119579A1
(de)
|
2007-05-31 |
2023-01-18 |
Genmab A/S |
Stabile igg4-antikörper
|
EP2615175B1
(de)
|
2007-05-31 |
2018-08-08 |
Genmab A/S |
Monovalente menschliche Antikörper
|
RS56743B1
(sr)
|
2007-08-21 |
2018-03-30 |
Amgen Inc |
Humani c-fms antigen vezujući proteini
|
EA201692127A1
(ru)
|
2007-11-07 |
2017-08-31 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающиеся с человеческим dec-205
|
CA2705923A1
(en)
|
2007-11-16 |
2009-05-22 |
Nuvelo, Inc. |
Antibodies to lrp6
|
EP2245052B1
(de)
|
2008-01-25 |
2017-05-24 |
Aarhus Universitet |
Selektive exosite-inhibierung der papp-a-aktivität gegenüber igfbp-4
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
EP3153524A1
(de)
|
2008-12-03 |
2017-04-12 |
Genmab A/S |
Antikörpervarianten mit modifikationen in der konstanten region
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
CA2778953C
(en)
|
2009-11-13 |
2020-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
EP2545077B1
(de)
|
2010-03-10 |
2018-10-31 |
Genmab A/S |
Monoklonale antikörper gegen c-met
|
MX339621B
(es)
|
2010-04-13 |
2016-06-02 |
Celldex Therapeutics Inc * |
Anticuerpos que se unen a cd27 humano y uso de los mismos.
|
CA2796055A1
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
Human fgf receptor and .beta.-klotho binding proteins
|
KR101930964B1
(ko)
|
2010-04-20 |
2018-12-19 |
젠맵 에이/에스 |
이종이량체 항체 fc-함유 단백질 및 그의 생산 방법
|
NZ604007A
(en)
|
2010-05-27 |
2015-03-27 |
Genmab As |
Monoclonal antibodies against her2 epitope
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
WO2011154453A1
(en)
|
2010-06-09 |
2011-12-15 |
Genmab A/S |
Antibodies against human cd38
|
EP3281956A3
(de)
|
2010-06-15 |
2018-04-18 |
Genmab A/S |
Menschliche antikörper-arzneimittelkonjugate gegen den gewebefaktor
|
MX354481B
(es)
|
2010-10-27 |
2018-03-07 |
Amgen Inc |
Anticuerpos dkk1 y métodos de uso.
|
US8906635B2
(en)
|
2011-02-28 |
2014-12-09 |
Northshore University Healthsystem |
Methods of diagnosing Clostridium difficile infection
|
MX2013010011A
(es)
|
2011-03-01 |
2014-10-24 |
Amgen Inc |
Agentes de unión biespecífica.
|
US9499610B2
(en)
|
2011-04-08 |
2016-11-22 |
H. Lundbeck A/S |
Antibodies specific to pyroglutamated Aβ
|
US20140170149A1
(en)
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
WO2012143523A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
US20140227265A1
(en)
|
2011-06-17 |
2014-08-14 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using clec-2
|
JP6454547B2
(ja)
|
2011-07-06 |
2019-01-16 |
ゲンマブ エー/エス |
抗体重鎖のc末端の修飾による補体依存性細胞傷害の調節
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
EP3674320A3
(de)
|
2011-10-27 |
2020-08-12 |
Genmab A/S |
Herstellung von heterodimeren proteinen
|
EP2788384B1
(de)
|
2011-12-08 |
2017-08-09 |
Amgen Inc. |
Agonistische menschliche lcat-antigenbindende proteine und ihre verwendung in der therapie
|
IL307989A
(en)
|
2012-04-27 |
2023-12-01 |
Novo Nordisk As |
Human CD30 ligand antigen-binding proteins
|
EP3632462A1
(de)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimerprotein mit dreifacher mutation
|
CN104736174B
(zh)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
KR20220156667A
(ko)
|
2013-01-10 |
2022-11-25 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
MX2015013181A
(es)
|
2013-03-15 |
2015-12-11 |
Amgen Inc |
Anticuerpos humanos pac1.
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
EP3166688A4
(de)
|
2014-07-08 |
2017-12-20 |
New York University |
Tau-bildgebungsliganden und deren verwendung in der diagnose und behandlung von tauopathie
|
KR102586656B1
(ko)
|
2014-07-11 |
2023-10-11 |
젠맵 에이/에스 |
Axl에 결합하는 항체
|
TW201620938A
(zh)
|
2014-09-15 |
2016-06-16 |
安美基公司 |
雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途
|
AU2015327819B2
(en)
|
2014-10-03 |
2021-07-01 |
Massachusetts Institute Of Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
EP3215527A4
(de)
|
2014-11-05 |
2018-04-18 |
Annexon, Inc. |
Humanisierte anti-komplementfaktor-c1q-antikörper und verwendungen davon
|
EP3945096A1
(de)
|
2014-12-19 |
2022-02-02 |
Regenesance B.V. |
Antikörper zur bindung von humanem c6 und verwendungen davon
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
EP3319993B1
(de)
|
2015-07-10 |
2020-01-15 |
Genmab A/S |
Axl-spezifische antikörper-wirkstoff-konjugate zur krebsbehandlung
|
GB201512215D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
JO3711B1
(ar)
|
2015-07-13 |
2021-01-31 |
H Lundbeck As |
أجسام مضادة محددة لبروتين تاو وطرق استعمالها
|
GB201512203D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
FI3334761T3
(fi)
|
2015-08-13 |
2023-08-14 |
Univ New York |
Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa
|
EP3350216A1
(de)
|
2015-09-15 |
2018-07-25 |
Amgen Inc. |
Tetravalente bispezifische und tetraspezifische antigenbindende proteine und verwendungen davon
|
JP6948330B2
(ja)
|
2015-12-23 |
2021-10-13 |
アムジエン・インコーポレーテツド |
胃抑制ペプチド受容体(gipr)に対する結合タンパク質をglp−1アゴニストと組み合わせて使用する、代謝障害の治療方法または寛解方法
|
JP7038064B2
(ja)
|
2016-04-18 |
2022-03-17 |
セルデックス セラピューティクス インコーポレイテッド |
ヒトcd40に結合するアゴニスト抗体およびその使用
|
CN116041504A
(zh)
|
2016-07-12 |
2023-05-02 |
H.隆德贝克有限公司 |
特异性针对过度磷酸化τ蛋白的抗体及其使用方法
|
MX2019004371A
(es)
|
2016-10-13 |
2019-11-18 |
Massachusetts Inst Technology |
Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos.
|
US20230137351A1
(en)
|
2016-11-14 |
2023-05-04 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
MX2019005594A
(es)
|
2016-11-15 |
2019-07-04 |
H Lundbeck As |
Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
|
CN110072888B
(zh)
|
2016-12-16 |
2023-07-18 |
H.隆德贝克有限公司 |
药剂、用途和方法
|
US10364286B2
(en)
|
2016-12-22 |
2019-07-30 |
H. Lundbeck A/S |
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
|
US11542337B2
(en)
|
2016-12-23 |
2023-01-03 |
Bristol Myers Squibb Company |
Therapeutic immunoglobulin G4 for improved bioanalytical and bioprocessing properties
|
EP3565836A1
(de)
|
2017-01-04 |
2019-11-13 |
H. Lundbeck A/S |
Für hypophosphoryliertes tau spezifische antikörper zur behandlung von augenerkrankungen
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
US10894833B2
(en)
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
IL307925A
(en)
|
2018-05-07 |
2023-12-01 |
Genmab As |
Combination of an antibody against 1-PD and conjugation of a drug with an antibody against TF for use in the treatment of cancer
|
EP3814379A4
(de)
|
2018-05-07 |
2022-03-30 |
Genmab A/S |
Verfahren zur behandlung von krebs mit einer kombination aus einem anti-pd-1-antikörper und einem antikörper-wirkstoff-konjugat gegen den gewebefaktor
|
KR20210086671A
(ko)
|
2018-10-30 |
2021-07-08 |
젠맵 에이/에스 |
항-vegf 항체 및 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
|
CN114174344A
(zh)
|
2019-05-30 |
2022-03-11 |
美国安进公司 |
工程改造铰链区以驱动抗体二聚化
|
MX2021015791A
(es)
|
2019-06-28 |
2022-04-01 |
Amgen Inc |
Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1.
|
TW202128160A
(zh)
|
2019-10-18 |
2021-08-01 |
美國加利福尼亞大學董事會 |
用於治療病原性血管病症之方法及組合物
|
JP2022554356A
(ja)
|
2019-11-04 |
2022-12-28 |
シージェン インコーポレイテッド |
抗cd30抗体薬物コンジュゲート及びhiv感染の処置のためのその使用
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法
|
CN115052890A
(zh)
|
2019-11-07 |
2022-09-13 |
展马博联合股份有限公司 |
使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合以治疗癌症的方法
|
WO2021092355A1
(en)
|
2019-11-08 |
2021-05-14 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-igg molecules
|
CA3160438A1
(en)
|
2019-11-19 |
2021-05-27 |
Amgen Inc. |
Novel multispecific antibody format
|
JP2023509373A
(ja)
|
2019-12-20 |
2023-03-08 |
ノヴァロック バイオセラピューティクス, リミテッド |
抗インターロイキン-23 p19抗体およびそれの使用方法
|
AU2021299947A1
(en)
|
2020-06-29 |
2022-12-22 |
Genmab A/S |
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
EP4200338A1
(de)
|
2020-08-20 |
2023-06-28 |
Amgen Inc. |
Antigenbindende proteine mit nichtkanonischem disulfid in der fab-region
|
US20230331867A1
(en)
|
2020-09-04 |
2023-10-19 |
Novarock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
WO2022076474A2
(en)
|
2020-10-07 |
2022-04-14 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
WO2022103773A1
(en)
|
2020-11-10 |
2022-05-19 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
CA3200671A1
(en)
|
2020-11-17 |
2022-05-27 |
Seagen Inc. |
Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
|
AU2022263406A1
(en)
|
2021-04-20 |
2023-10-19 |
Amgen Inc. |
Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
|
WO2023076989A1
(en)
|
2021-10-29 |
2023-05-04 |
Seagen Inc. |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
|
WO2023213960A1
(en)
|
2022-05-06 |
2023-11-09 |
Genmab A/S |
Methods of treating cancer with anti-tissue factor antibody-drug conjugates
|
WO2024013723A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|